These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 7199476)
21. Sialic acids in human lymphocytes. Qualitative and quantitative alterations in cancer cases. Holzhauser R; Faillard H Carbohydr Res; 1988 Nov; 183(1):89-95. PubMed ID: 3233599 [TBL] [Abstract][Full Text] [Related]
22. Melanoma inhibitory activity (MIA), a serological marker of malignant melanoma. Bosserhoff AK; Dreau D; Hein R; Landthaler M; Holder WD; Buettner R Recent Results Cancer Res; 2001; 158():158-68. PubMed ID: 11092043 [TBL] [Abstract][Full Text] [Related]
23. S100 protein serum levels in cutaneous malignant melanoma. Seregni E; Massaron S; Martinetti A; Illeni MT; Rovini D; Belli F; Agresti R; Greco M; Cascinelli N; Bombardieri E Oncol Rep; 1998; 5(3):601-4. PubMed ID: 9538159 [TBL] [Abstract][Full Text] [Related]
24. [Determination of lipid-bound sialic acid levels in the diagnosis of recurrences of cancer of the rectum]. Ozhiganov EL; Novikov AM; Bassilyk LS Lab Delo; 1987; (3):204-7. PubMed ID: 2438465 [No Abstract] [Full Text] [Related]
25. S100 serum level: a tumour marker for metastatic melanoma. Bottoni U; Izzo P; Richetta A; Mannooranparampil TJ; Devirgiliis V; Del Giudice M; Reale MG; Frati L; Calvieri S Melanoma Res; 2003 Aug; 13(4):427-9. PubMed ID: 12883371 [No Abstract] [Full Text] [Related]
26. Correlation between lipid-associated sialic acid and tumor burden in melanoma. Buzaid AC; Sandler AB; Hayden CL; Scinto J; Poo WJ; Clark MB; Hotchkiss S Int J Biol Markers; 1994; 9(4):247-50. PubMed ID: 7836804 [TBL] [Abstract][Full Text] [Related]
27. The circulating microRNA-221 level in patients with malignant melanoma as a new tumor marker. Kanemaru H; Fukushima S; Yamashita J; Honda N; Oyama R; Kakimoto A; Masuguchi S; Ishihara T; Inoue Y; Jinnin M; Ihn H J Dermatol Sci; 2011 Mar; 61(3):187-93. PubMed ID: 21273047 [TBL] [Abstract][Full Text] [Related]
28. Serum concentrations of magnesium, potassium, calcium and sodium in patients with malignant melanoma . Pankow B; Pankow D; Fischer U; Richter M Dermatol Monatsschr; 1978 Nov; 164(11):813-4. PubMed ID: 720713 [No Abstract] [Full Text] [Related]
29. Melanin inclusions in the peripheral blood leukocytes of a patient with malignant melanoma. Weil SC; Holt S; Hrisinko MA; Little L; DeBacker N Am J Clin Pathol; 1985 Nov; 84(5):679-81. PubMed ID: 4061395 [TBL] [Abstract][Full Text] [Related]
30. [Copper content and the ceruloplasmin activity in the blood in melanoma of the skin]. Sergeev SI; Kochetkova MK; Romanova OA Vopr Onkol; 1978; 24(10):61-5. PubMed ID: 716320 [TBL] [Abstract][Full Text] [Related]
32. Usefulness of serum 5-S-cysteinyl-dopa as a biomarker for predicting prognosis and detecting relapse in patients with advanced stage malignant melanoma. Umemura H; Yamasaki O; Kaji T; Otsuka M; Asagoe K; Takata M; Iwatsuki K J Dermatol; 2017 Apr; 44(4):449-454. PubMed ID: 27786364 [TBL] [Abstract][Full Text] [Related]
33. Parathyroid hormone-related protein in patients with malignant melanoma. Elias AN; Pandian MR; Jacowatz J Arch Dermatol; 1992 Feb; 128(2):278-9. PubMed ID: 1739318 [No Abstract] [Full Text] [Related]
35. [Studies on correlation between alterations in serum sialic acid levels and remission, metastasis, and recurrence of diseases in patients with cancer (author's transl)]. Chen YQ; Zhou YQ; Yu SY Zhonghua Zhong Liu Za Zhi; 1979; 1(1):29-34. PubMed ID: 552354 [No Abstract] [Full Text] [Related]
36. Prediagnostic serum levels of 1,25-dihydroxyvitamin D and malignant melanoma. Cornwell ML; Comstock GW; Holick MF; Bush TL Photodermatol Photoimmunol Photomed; 1992 Jun; 9(3):109-12. PubMed ID: 1300138 [TBL] [Abstract][Full Text] [Related]
37. [Sialic acids in lymphogranulomatosis]. Novikov AM; Sorokin EN; Bassalyk LS Ter Arkh; 1984; 56(6):75-7. PubMed ID: 6474378 [No Abstract] [Full Text] [Related]
38. [S-100B and MIA (melanoma inhibiting activity) serum proteins: a prospective study of their value as melanoma progression markers]. Dornier C; Dousset B; Legras B; Barbaud A; Schmutz JL Ann Dermatol Venereol; 2002 May; 129(5 Pt 1):739-40. PubMed ID: 12124520 [No Abstract] [Full Text] [Related]
39. Indoleamine 2,3 dioxygenase as a prognostic and follow-up marker in melanoma. A comparative study with LDH and S100B. de Lecea MV; Palomares T; Al Kassam D; Cavia M; Geh JLC; de Llano P; Muñiz P; Armesto D; Martinez-Indart L; Alonso-Varona A J Eur Acad Dermatol Venereol; 2017 Apr; 31(4):636-642. PubMed ID: 27633490 [TBL] [Abstract][Full Text] [Related]
40. [Changes in serum sialic acid levels in patients with ovarian tumors in the process of treatment]. Travnikov ME; Novikov AM; Varazashvili LM; Bassalyk LS; Kozachenko VP Akush Ginekol (Mosk); 1990 Jul; (7):61-3. PubMed ID: 2240453 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]